This Week on NeurologyLive® — October 19, 2026 Isabella Ciccone, MPH

Published Date: 21 Oct 2026

Here's some of what is coming soon to NeurologyLive® this week.

Read Full News

Latest News

Nipocalimab in Myasthenia Gravis: Real-World Use, Long-Term Safety, and the Road Ahead Marco Meglio, Leonard Dragone, MD, PhD

Leonard Dragone, MD, PhD, Disease Area Leader at Johnson & Johnson, discusses how nipocalimab is being incorporated into generalized MG care, what long-term data show, and where J&J sees the therapy’s role evolving.

RGX-202 Meets Primary End Point in Phase 3 Duchenne Trial Louie Pasculli

Pivotal AFFINITY DUCHENNE results showed microdystrophin expression above the prespecified threshold in 93% of evaluable participants, with preliminary functional findings favoring treatment over external controls.

NeurologyLive® Friday 5 — October 16, 2026 Isabella Ciccone, MPH

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending October 16, 2026.

FDA Approves Autoinjector for Self-Administered Zilucoplan in Generalized Myasthenia Gravis Marco Meglio

Adults with generalized myasthenia gravis who are anti-acetylcholine receptor antibody positive now have a second self-administration option for the complement inhibitor zilucoplan.

Levacetylleucine Shows Sustained Benefit at 3 Years in Niemann-Pick Disease Marco Meglio

Three-year extension data from the phase 3 IB1001-301 trial show levacetylleucine slowed disease progression in both adults and children with Niemann-Pick disease type C.

Episode 177: Previewing the 2026 NEALS Annual Meeting Marco Meglio, Jinsy A. Andrews, MD, MSc, Nicholas Maragakis, MD

Mind Moments®, a podcast from NeurologyLive®, brings you an exclusive interview with Nicholas J. Maragakis, MD; and Jinsy Andrews, MD, MSc, FAAN, FANA. [LISTEN TIME: 23 minutes]

Todays Updates

ENCORE: Early ALIS Cuts MACLD Recurrence, With Jakko Van Ingen, MD, PhD Jakko Van Ingen, MD, PhD

van Ingen, of Radboud University Medical Center discusses data showing add-on ALIS improved durable culture conversion in newly diagnosed MAC lung disease.

ENCORE ALIS Data Could Reshape First-Line MACLD: Jakko van Ingen, MD, PhD Jakko Van Ingen, MD, PhD

van Ingen, of Radboud University Medical Center, discusses the ENCORE trial's patient-reported endpoint for ALIS in MAC lung disease.

Mepolizumab Cuts COPD Exacerbations Across Smoking Status: Claus Vogelmeier, MD Claus Vogelmeier, MD

Vogelmeier, of Philipps-University of Marburg discusses pooled data showing reduced COPD exacerbations, though most effectively in former smokers.

Examining the Oral Steroid Burden in Asthma and COPD

Examining the Oral Steroid Burden in Asthma and COPD

Short Telomeres Linked to UIP Pattern, Not Fibrosis Extent, in ILD

Short Telomeres Linked to UIP Pattern, Not Fibrosis Extent, in ILD

CHEST 2026: Day 2 Recap — 4 Headlines to Know

CHEST 2026: Day 2 Recap — 4 Headlines to Know

NeurologyLive® Brain Games: October 18, 2026 Louie Pasculli

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is biomarkers in multiple sclerosis!

Todays Updates

ENCORE: Early ALIS Cuts MACLD Recurrence, With Jakko Van Ingen, MD, PhD Jakko Van Ingen, MD, PhD

van Ingen, of Radboud University Medical Center discusses data showing add-on ALIS improved durable culture conversion in newly diagnosed MAC lung disease.

ENCORE ALIS Data Could Reshape First-Line MACLD: Jakko van Ingen, MD, PhD Jakko Van Ingen, MD, PhD

van Ingen, of Radboud University Medical Center, discusses the ENCORE trial's patient-reported endpoint for ALIS in MAC lung disease.

Mepolizumab Cuts COPD Exacerbations Across Smoking Status: Claus Vogelmeier, MD Claus Vogelmeier, MD

Vogelmeier, of Philipps-University of Marburg discusses pooled data showing reduced COPD exacerbations, though most effectively in former smokers.

Examining the Oral Steroid Burden in Asthma and COPD

Examining the Oral Steroid Burden in Asthma and COPD

Short Telomeres Linked to UIP Pattern, Not Fibrosis Extent, in ILD

Short Telomeres Linked to UIP Pattern, Not Fibrosis Extent, in ILD

CHEST 2026: Day 2 Recap — 4 Headlines to Know

CHEST 2026: Day 2 Recap — 4 Headlines to Know

NeurologyLive® Brain Games: October 18, 2026 Louie Pasculli

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is biomarkers in multiple sclerosis!

Latest News

Leonard Dragone, MD, PhD, Disease Area Leader at Johnson & Johnson, discusses how nipocalimab is being incorporated into generalized MG care, what long-term data show, and where J&J sees the therapy’s role evolving.

Pivotal AFFINITY DUCHENNE results showed microdystrophin expression above the prespecified threshold in 93% of evaluable participants, with preliminary functional findings favoring treatment over external controls.

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending October 16, 2026.

Adults with generalized myasthenia gravis who are anti-acetylcholine receptor antibody positive now have a second self-administration option for the complement inhibitor zilucoplan.

Three-year extension data from the phase 3 IB1001-301 trial show levacetylleucine slowed disease progression in both adults and children with Niemann-Pick disease type C.

Mind Moments®, a podcast from NeurologyLive®, brings you an exclusive interview with Nicholas J. Maragakis, MD; and Jinsy Andrews, MD, MSc, FAAN, FANA. [LISTEN TIME: 23 minutes]

News All Time

Telitacicept Shows Deepening, Durable Response in Myasthenia Gravis Marco Meglio

New 48-week phase 3 data show many patients with generalized myasthenia gravis reached minimal symptom expression on telitacicept, and most who did sustained it.

Individualizing Advanced Therapies in Parkinson Disease: Hubert Fernandez, MD Hubert Fernandez, MD, Louie Pasculli

The director of the Center for Neurological Restoration at Cleveland Clinic discusses when to transition beyond oral medication and considerations for selecting device-aided therapies in PD.

This Week on NeurologyLive® — October 12, 2026 Isabella Ciccone, MPH

Here's some of what is coming soon to NeurologyLive® this week.

NeurologyLive® Brain Games: October 11, 2026 Louie Pasculli

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is recent therapeutic advances in MS!

Frontotemporal Dementia Diagnosis, Head Impacts, and Emerging Treatment Approaches Louie Pasculli, Carme Tartaglia, MD

Carmela Tartaglia, MD, FRCPC, discusses the challenges of diagnosing frontotemporal dementia, the evolving role of biomarkers, and emerging approaches to disease modification.

NeurologyLive® Friday 5 — October 9, 2026 Isabella Ciccone, MPH

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending October 9, 2026.

Phase 4 THRIVE Data Highlights Eptinezumab’s Impact on Migraine After Prior CGRP Failure Marco Meglio

Newly announced Phase 4 THRIVE trial results showed most patients who previously had an inadequate response to a CGRP-targeting therapy improved with eptinezumab over 24 weeks.

FDA Action Update, September 2026: Approvals, Clearances, and Priority Review Isabella Ciccone, MPH

Catch up on any of the neurology headlines you may have missed in September 2026, compiled into 1 place by the NeurologyLive® team.

Solengepras Meets Primary Endpoint in Phase 3 ARISE Trial of Parkinson Disease Marco Meglio

Phase 3 ARISE trial results show solengepras 150 mg significantly reduced OFF time and improved motor and non-motor symptoms in Parkinson disease.

CSF Biomarkers Identify Shared LRRK2 Pathway Activation in Sporadic and LRRK2-Associated Parkinson Disease Louie Pasculli

New cerebrospinal fluid biomarker data suggest shared LRRK2 pathway activation across sporadic and LRRK2-associated Parkinson disease, potentially informing biomarker development and therapeutic targeting.

Metabolic Agent Vutiglabridin Improves Motor Scores in Early-Stage Study of Parkinson Disease Marco Meglio

Phase 2a trial results showed 800 mg vutiglabridin significantly improved motor symptom scores compared with placebo in early-stage Parkinson's disease.

Christen Kutz, PhD, PA-C, on What Real-World Data Reveal About Treatment Transitions to Nipocalimab in Generalized Myasthenia Gravis Marco Meglio, Christen Kutz, PhD, PA-C

Christen Kutz, PhD, PA-C, discusses a retrospective survey of neurology providers examining why patients with generalized myasthenia gravis are transitioning to nipocalimab and what real-world outcomes data suggest about its role in the treatment landscape.

New Study Reveals Plasma Biomarkers Highlight Distinct Biological Responses to Lecanemab in Alzheimer Disease Louie Pasculli, Carlos Cruchaga, PhD

Carlos Cruchaga, PhD, director of the NeuroGenomics and Informatics Center at Washington University, discusses emerging blood-based biomarkers for monitoring biological and cognitive responses to lecanemab treatment in Alzheimer disease.

Brain Chat: The Overlap Years: Perimenopause, Menopause, and MS Mitzi Joi Williams, MD

Mitzi Joi Williams, MD, is joined by Jakai McEwen, DO, and Charnetta Colton-Poole, MD, to discuss the challenges of communication between patients and their health care teams, including navigating medical language, promoting shared decision-making, and advocating for clear, patient-centered care.

Advanced Therapies in Parkinson Disease: Matching the Right Treatment to the Right Patient Hubert Fernandez, MD, Louie Pasculli

An MDS 2026 plenary speaker discusses the evolving role of infusion therapies, deep brain stimulation, and focused ultrasound in Parkinson disease, including when to consider device-aided therapies and how treatment selection can be individualized.

Emerging Advances in Parkinson Disease Ahead of MDS 2026: Benjamin Walter, MD, MBA Benjamin L. Walter, MD, Louie Pasculli

Benjamin Walter, MD, MBA, discusses how advances in biomarker testing and genetic characterization are informing Parkinson disease care, alongside developments in adaptive deep brain stimulation and efforts to identify disease earlier.

Recommended News For You

Is Vitamin D a Key to Better Breast Cancer Survival?

Liposomal Chemo Combination No Better Than Standard Induction in Pediatric AML

Breast cancer: A new target to eliminate dormant cells before they wake

Many Americans unaware of links between HPV and cancers, poll reveals

Black women are more likely to die of breast cancer. Close the gap by looking into mammogram studies.

Advanced imaging, targeted therapy help men with prostate cancer safely defer surgery and radiation therapy

Immunotherapy in Head and Neck Cancer After Failure of Definitive Therapy.

Recommended Articles For You

A Novel Gemcitabine-Releasing Intravesical System for Intermediate-Risk Non-Muscle-Invasive Bladder Cancer 

Prognostic Patterns of Functional Recovery During Long-Term Cancer Survivorship 

The Importance of Having a Quick and Effective Heparin Antidote  

Hematopoietic Immune Microenvironment Plasticity: Mechanisms, Clinical Implications, and Emerging Therapeutics 

Whats more on Hidoc Dr.

Medical Updates
KOL Videos
Surveys
Events

Daily news to keep you up to date

Gain valuable insights with our in-depth KOL Video discussions

Participate and win cash vouchers

Get updates on the latest events happening around the world
Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

MCh in Surgical Oncology: Admission, Medical School, Fees, Qualifications Information

2.

Blood Cancer's First New Drug in 29 Years; AI for Mammography? Phase III Myeloma Win

3.

ASCO Future Focus: Follicular Lymphoma: Future Focus from the American Society of Clinical Onology

4.

There is a 40% reduction in the risk of 9 cancers with good cardiorespiratory fitness.

5.

WHO releases new R&D landscape analyses highlighting gaps and inequities in cancer research

1.

ERASur: Evaluating Total Ablative Therapy in Limited Metastatic Colorectal Cancer

2.

Strategic Solutions in Oncology for Modern Medicine

3.

Tumor Microenvironment Mapping in Cancer Care

4.

Malignant Prolactinoma: Prolactin Surge with Minimal Growth Masks Widespread Metastases

5.

Emerging Therapies Using Tumor Evolution Interruption Technologies

1.

International Conference on Innovations in Critical Care for Oncology and Cardiology

2.

International Conference on Oncology, Cardiology and Critical Care Policy

3.

International Conference on Oncology, Cancer Prevention and Public Health

4.

International Conference on Cancer Nursing and Rehabilitation Strategies

5.

International Conference on Best Practices in Oncology, Cardiology and Critical Care

1.

ESMO Breast Cancer 2022: P Reality X- A Restrospective Analysis

2.

Guideline Recommendations of Lorlatinib as First-Line Treatment for ALK+ NSCLC

3.

CNS Clarity from Day One: Rethinking Early Diagnostic Strategies in ALK+NSCLC

4.

Management of 1st line ALK+ mNSCLC (CROWN TRIAL Update) - Part V

5.

Current Cancer Scenario in India- Importance of Genomic Testing & Advancement in Diagnosis and Treatment

Fastest Growing Medical Platform for Doctors

Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801

Phone :
+1-415-463-3094

Email :
anishagadia@hidoc.co

Quick Links

Drug DatabaseDrug InteractionDiseases Database
KOL VideosKnowledge HubQuizzes
Medical UpdatesEventsAbout Us

© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
Home
Profile
Login
bot